Business Description
Alar Pharmaceuticals Inc
ISIN : TW0006785009
Share Class Description:
ROCO:6785: Ordinary SharesTotal Employee Number:
21Description
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 857.9 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 38.42 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 43.1 | |||||
3-Year EBITDA Growth Rate | -29.1 | |||||
3-Year EPS without NRI Growth Rate | -50.4 | |||||
3-Year FCF Growth Rate | -63.2 | |||||
3-Year Book Growth Rate | 58.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.34 | |||||
9-Day RSI | 42.84 | |||||
14-Day RSI | 40.08 | |||||
3-1 Month Momentum % | -15.61 | |||||
6-1 Month Momentum % | -57.57 | |||||
12-1 Month Momentum % | -36.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 25.01 | |||||
Quick Ratio | 25.01 | |||||
Cash Ratio | 24.6 | |||||
Days Sales Outstanding | 31.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward Dividend Yield % | 0.1 | |||||
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.59 | |||||
Operating Margin % | -6290.64 | |||||
Net Margin % | -3755.25 | |||||
EBITDA Margin % | -3338.03 | |||||
FCF Margin % | -5103.6 | |||||
OCF Margin % | -5103.6 | |||||
ROE % | -4.65 | |||||
ROA % | -4.49 | |||||
ROIC % | -138.67 | |||||
3-Year ROIIC % | -131.18 | |||||
ROC (Joel Greenblatt) % | -673.29 | |||||
ROCE % | -4.34 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 600 | |||||
PS Ratio | 2222.22 | |||||
PB Ratio | 2.82 | |||||
Price-to-Tangible-Book | 2.82 | |||||
EV-to-EBIT | -41.4 | |||||
EV-to-EBITDA | -43.69 | |||||
EV-to-Revenue | 1458.28 | |||||
EV-to-FCF | -28.57 | |||||
Price-to-GF-Value | 1.03 | |||||
| Price-to-Net-Current-Asset-Value | 2.99 | |||||
| Price-to-Net-Cash | 3.04 | |||||
Earnings Yield (Greenblatt) % | -2.42 | |||||
FCF Yield % | -2.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alar Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 3.003 | ||
| EPS (TTM) (NT$) | -1.7 | ||
| Beta | 0.5825 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 73.99 | ||
| 14-Day RSI | 40.08 | ||
| 14-Day ATR (NT$) | 3.664869 | ||
| 20-Day SMA (NT$) | 102.19 | ||
| 12-1 Month Momentum % | -36.06 | ||
| 52-Week Range (NT$) | 92 - 317 | ||
| Shares Outstanding (Mil) | 66.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alar Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alar Pharmaceuticals Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 0.100000 Cash Dividend | 2026-08-25 | In 8 days | ||
| TWD 0.250000 Cash Dividend | 2025-06-10 | 148.00 (-1.66%) |
Show
Entries
Alar Pharmaceuticals Inc Frequently Asked Questions
What is Alar Pharmaceuticals Inc(ROCO:6785)'s stock price today?
The current price of ROCO:6785 is NT$100.00. The 52 week high of ROCO:6785 is NT$317.00 and 52 week low is NT$92.00.
When is next earnings date of Alar Pharmaceuticals Inc(ROCO:6785)?
The next earnings date of Alar Pharmaceuticals Inc(ROCO:6785) is .
Does Alar Pharmaceuticals Inc(ROCO:6785) pay dividends? If so, how much?
Alar Pharmaceuticals Inc(ROCO:6785) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alar Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers